Last reviewed · How we verify

NCT04920812: MITOMICS

MITOMICS : a Multi-OMICS Approach for the Diagnosis of Mitochondrial Diseases

Recruiting now Last updated 25 February 2025
What this trial tests

trial testing diagnosis of mitochondrial myopathy in Mitochondrial Diseases in 66 participants. Currently enrolling.

Timeline
7 March 2022
Primary endpoint
7 March 2022
7 September 2025

Quick facts

Lead sponsorCentre Hospitalier Universitaire de Nice
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment66
Start date7 March 2022
Primary completion7 March 2022
Estimated completion7 September 2025
Sites9 locations across France

Drugs / interventions tested

Conditions studied

Sponsor

Centre Hospitalier Universitaire de Nice

Who can join

Eligibility, any sex, with Mitochondrial Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

MITOMICS aims to determine which RNA-Seq results (from muscle or fibroblasts) are the most informative for the interpretation of VUS identified by WES for patients suspected of mitochondrial myopathy. Analysis of RNA-Seq and WES results will performed with a computational approach using an autoencoder-based method

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Mitochondrial Diseases

Currently open trials in the same condition.

Other Centre Hospitalier Universitaire de Nice trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04920812.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing